SLIT2 and breast cancer: Furthermore, the mean interval (from diagnosis of breast cancer to brain metastasis) and mean survival (from diagnosis of brain metastasis to death) were both significantly shorter in patients with low expression of Slit2 or Robo1 than the high expression group.